Anal HPV in Kidney Transplant Recipients: A Closer Look at Pathogenesis and Clinical Management
Pathogens · 14.08.2026 · 15 (8) · 848
DOI: 10.3390/pathogens15080848 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 14.08.2026. Verfasst von Sonia Moretti und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Health, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, Papillomavirus Infections, Human Papillomavirus Viruses, Anus Neoplasms. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kidney transplant recipients (KTRs) face a significantly elevated risk of persistent high-risk human papillomavirus (HR-HPV) infection and subsequent anal squamous cell carcinoma (ASCC) due to chronic immunosuppressive therapy impairing immunosurveillance. Despite the markedly increased risk of ASCC in this vulnerable cohort, standardized screening protocols and optimal clinical management guidelines are not exhaustive. Chronically compromised immunosurveillance permits prolonged HR-HPV carriage and viral genome integration, driving oncogenesis via the E6 and E7 oncoproteins. While calcineurin inhibitors exert pro-oncogenic effects, transitioning to mTOR inhibitors offers distinct antiproliferative and antiviral advantages. Early detection relies on risk-stratified screening utilizing digital anorectal examination, anal cytology, and high-resolution anoscopy. For managing anal intraepithelial neoplasia, traditional topical agents and minimally invasive ablative procedures are widely used, although high recurrence rates present a major clinical challenge. This review analyzes HPV pathogenesis and clinical management in KTRs, evaluating the impact of immunosuppressive regimens and exploring innovative diagnostic and therapeutic strategies. To address viral persistence without compromising the allograft, integrating novel non-invasive, target-specific nutraceuticals may represent an interesting complementary approach. Ultimately, mitigating post-transplant ASCC requires a multidisciplinary strategy that couples early localized screening with tailored systemic immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Health, 00161 Rome, Italy.
- Department of Obstetrics and Gynecology, San Salvatore Hospital, 67100 L'Aquila, Italy.
- Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila Surgical Coloproctology Hospital Val Vibrata, 64027 Sant'Omero, Italy.
- Department of Gynecology and Obstetrics, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
ORCID-Profile: Renato Pietroletti, Vittorio Unfer
Zitieren
APA
Moretti, S., Pavone Cossut, M. R., Tiberi, A., Pietroletti, R., & Unfer, V. (2026). Anal HPV in Kidney Transplant Recipients: A Closer Look at Pathogenesis and Clinical Management. Pathogens, 15(8), 848. https://doi.org/10.3390/pathogens15080848
Vancouver
Moretti S, Pavone Cossut MR, Tiberi A, Pietroletti R, Unfer V. Anal HPV in Kidney Transplant Recipients: A Closer Look at Pathogenesis and Clinical Management. Pathogens. 2026;15(8):848. doi:10.3390/pathogens15080848
BibTeX
@article{Moretti2026,
author = {Moretti, Sonia and Pavone Cossut, Maria Rosaria and Tiberi, Annalisa and Pietroletti, Renato and Unfer, Vittorio},
title = {Anal HPV in Kidney Transplant Recipients: A Closer Look at Pathogenesis and Clinical Management},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {8},
pages = {848},
doi = {10.3390/pathogens15080848}
}
EUVIMED